What high risk high reward psychedelic drug companies

There are several high risk high reward psychedelic drug companies that are worth considering: 1. **Compass Pathways (CMPS)**: This company is developing psilocybin therapy for treatment-resistant depression (TRD) and has a successful Phase 3 clinical trial underway. The potential market share for TRD is substantial, and the company's lead product, COMP360, could have significant revenue potential if approved. 2. **Mind Medicine (MNMD)**: With three clinical-stage programs, including MM-120 using LSD, Mind Medicine is diversifying its portfolio across different psychedelic substances. Their lead candidate, MM-120, shows promise in treating various therapeutic areas. 3. **Cybin (CYBN)**: Cybin is developing two clinical-stage psilocybin therapies, CYB003 and CYB004, with preclinical testing for other psychedelic candidates. The company has a strong focus on research and development. 4. **Atai Life Sciences (ATAI)**: Atai is developing multiple drugs based on psychedelic substances, including ibogaine and ketamine. Their diversified pipeline and strategic partnerships position them as a key player in the psychedelic drug market. These companies are at the forefront of the psychedelic drug industry, and their high risk high reward nature reflects the potential for substantial returns for investors willing to take on the associated risks.